Compounded semaglutide vs brand name Wegovy: what is the real difference?

Short answer Wegovy is the FDA‑approved, branded semaglutide product made and controlled by Novo Nordisk. “Compounded semaglutide” is made by independent pharmacies from bulk active ingredient and is not FDA‑approved. The active ingredient can be the same molecule, but the products differ in regulation, manufacturing controls, device, labeling, stability testing, and (therefore) safety and predictability.

Key differences

• Regulatory status and oversight

  • Wegovy: FDA‑approved. Manufactured under strict GMP controls, with lot testing, approved labeling and known stability/shelf‑life.
  • Compounded: Not FDA‑approved as a finished drug. State boards and the compounding pharmacy regulate it, and oversight is less uniform. Compounded products can vary between pharmacies.

• Formulation, delivery device, and dosing accuracy

  • Wegovy: Supplied in prefilled, calibrated pens designed for once‑weekly dosing and a specific titration schedule (starting low, ramping to 2.4 mg weekly). Pens are validated for dose accuracy and patient use.
  • Compounded: Often dispensed as multi‑dose vials or prefilled syringes made in the pharmacy. Dosing accuracy (drawing correct dose, variability between batches) and device quality may vary.

• Purity, sterility, and stability

  • Wegovy: Batch tested for purity, potency and sterility; stability studies support the labeled storage and beyond‑use periods.
  • Compounded: Depends on the pharmacy’s processes. Risks include incorrect potency, contamination, or shorter/uncertain shelf life. Some pharmacies provide certificates of analysis (COAs); others do not.

• Evidence of safety and efficacy

  • Wegovy: Backed by large randomized trials showing weight‑loss efficacy and a known side‑effect profile.
  • Compounded: No clinical trial data to demonstrate equivalence to Wegovy; safety and efficacy are inferred from the active ingredient but not proven for the specific compounded product.

• Legal, insurance and supply issues

  • Wegovy: Patented product, often expensive and sometimes limited supply; insurance coverage for weight loss varies.
  • Compounded: Typically cheaper, sometimes easier to obtain, but insurance usually won’t cover it; legal/ethical issues can arise if a compound is intended to be a substitute for a commercially available product.

Risks with compounded semaglutide

• Variable potency (too low = no benefit; too high = increased adverse events)
• Contamination or non‑sterile preparation (infection risk)
• Incorrect or unsafe excipients or containers
• Lack of device training/support (no manufacturer patient support program)
• Possible legal or supply‑chain issues if the API is sourced improperly (e.g., “research only” material)

When a compounded product might be reasonable

• If Wegovy is unavailable or unaffordable and you cannot access a legal, approved alternative, some patients use compounded semaglutide — but only after careful risk/benefit discussion with a clinician.

How to reduce risk if you consider compounded semaglutide

• Use a reputable, licensed compounding pharmacy with sterile injectables experience.
• Prefer pharmacies accredited for compounding (look for Pharmacy Compounding Accreditation Board — PCAB — or similar accreditation).
• Ask the pharmacy for: certificate of analysis (COA) for the batch/API source, evidence of sterile compounding practices (USP <797> compliance), beyond‑use date and storage instructions, and details on the delivery format (vial vs prefilled syringe) and how to handle/dose safely.
• Buy only with a legitimate prescription and through a verified pharmacy — avoid unverified online sellers or “research”‑grade product.
• Discuss dosing, injection technique, and monitoring with your prescriber; watch for side effects (nausea, pancreatitis signs, gallbladder issues, thyroid concerns) and get appropriate follow‑up.

Specific brands/services to consider

• Wegovy (Novo Nordisk): FDA‑approved for weight loss; recommended when you want a product with known clinical trial support, standardized pens, and manufacturer support.
• Ozempic (Novo Nordisk): The same active molecule for diabetes; occasionally used/considered in dosing discussions by prescribers (different labeled indications and dosing). Rybelsus (oral semaglutide) is another branded form for diabetes.
• If using compounding: use a PCAB‑accredited compounding pharmacy (search “PCAB accredited pharmacies”) and confirm USP <797> sterile compounding compliance. Also check your state board of pharmacy and the FDA website for any advisories about semaglutide compounding.

Bottom line If you want the most predictable safety and efficacy, Wegovy (Novo Nordisk) is the safer, evidence‑backed choice. Compounded semaglutide can be less expensive or more accessible but carries added risks (potency, sterility, stability, lack of formal approval). If you consider a compounded product, only use a well‑accredited compounding pharmacy, get documentation (COA, sterile compounding practices), and coordinate closely with your clinician.

If you’d like, tell me whether you’re evaluating this for cost reasons, access, or side effects, and I can help you weigh options (insurance appeals, patient assistance programs, or vetted compounding resources).